Innoxel Lifesciences Successfully Completes EU GMP Inspection by Belgium's FAMHP

Bharat Parenterals Limited's subsidiary, Innoxel Lifesciences, is pleased to announce the successful completion of the European Union Good Manufacturing Practice (EU GMP) inspection conducted by the Federal Agency for Medicines and Health Products, Belgium (FAMHP).

The inspection was carried out at the company's manufacturing facility from 24th November 2025 to 28th November 2025. The audit was completed with zero critical and zero major observations, reflecting the company's strong quality systems, robust manufacturing infrastructure, and strict adherence to global regulatory standards.

This milestone further strengthens the company's regulatory credentials following its earlier successful USFDA inspection outcomes and reinforces its position as a trusted partner in regulated international markets.

Commenting on the development, the management said: "Successfully completing the EU GMP inspection by the FAMHP, Belgium with zero critical and zero major observations is a testament to our teams' dedication to quality and compliance. This achievement enhances our ability to serve regulated markets and supports our long-term strategic growth objectives."

Bharat Parenterals and Innoxel Lifesciences remain commiƩed to expanding their global footprint through continued investments in quality, systems, and regulatory excellence.

Shares of Bharat Parenterals Ltd was last trading in BSE at Rs. 1105.95 as compared to the previous close of Rs. 1106.95. The total number of shares traded during the day was 123 in over 16 trades.

The stock hit an intraday high of Rs. 1122.95 and intraday low of 1076.30. The net turnover during the day was Rs. 134902.00.

Source : Equity Bulls

Keywords

BharatParenterals INE365Y01019 Pharmaceuticals InnoxelLifesciences EUGMP Inspection Belgium FAMHP